-transparent.png){kind=logo}
Sulindac (cis-5-fluoro-2-methyl-l-[(p-methyl sulfinyl)-benzylidene]-indene-3-acetic acid) is a new nonsteroidal antirheumatic drug recently evaluated in a double-blind trial of 91 patients with hip osteoarthritis. Consecutive patients with documented flare following previous drug withdrawal were randomly assigned to one of 3 treatment groups: (1) sulindac given twice daily, (2) sulindac given 4 times daily, and (3) placebo. The dosage of sulindac, 100 to 300 mg daily, was adjusted according to patient global response and tolerance at 3- to 7-day intervals over 3 wk. Of 15 efficacy measurements evalulated, there was no difference between sulindac given 2 or 4 times daily, but differences were disclosed between one or both sulindac treatment groups and placebo in 11 of the 15 efficacy measurements (p less than 0.05, less than 0.01). The frequency of adverse reactions was of the same order for each treatment group. These included gastrointestinal upset, rash, and dizziness, usually transient and mild to moderate in severity. Serial laboratory studies revealed no evidence of renal, hepatic, or hematopoietic toxicity.
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
April 1979,
Ryumachi. [Rheumatism],
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
August 1981,
Rheumatology and rehabilitation,
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
January 1979,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
March 2009,
Arthritis and rheumatism,
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
February 2013,
Archives of physical medicine and rehabilitation,
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
May 1976,
Rheumatology and rehabilitation,
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
May 2024,
Annals of internal medicine,
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
January 1983,
Current medical research and opinion,
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
October 2018,
Arthritis & rheumatology (Hoboken, N.J.),
J J Calabro, and
S Y Andelman, and
J R Caldwell, and
R C Gerber, and
D Hamaty, and
H Kaplan, and
B A Maltz, and
J L Parsons, and
P Saville, and
H C Tretbar, and
J R Ward
January 1977,
Current medical research and opinion,
